Matching articles for "April 6"
Issue 1310 · April 20, 2009 Free
Correction: Vancomycin Dosing and Monitoring

(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):32
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L .
Issue 1309 · April 6, 2009
Vancomycin Dosing and Monitoring

Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin ( Vancocin , and others) were recently published. IV vancomycin has been used for decades as an alternative to…

Med Lett Drugs Ther. 2009 Apr 6; 51(1309):25
Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin ( Vancocin , and others) were recently published. IV vancomycin has been used for decades as an alternative to penicillins for treatment of serious infections due to gram-positive cocci. In recent years, the widest use of the drug has been for treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
Issue 1309 · April 6, 2009
Deep Brain Stimulation for Parkinson's Disease

Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently…

Med Lett Drugs Ther. 2009 Apr 6; 51(1309):26-7
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Issue 1309 · April 6, 2009
Valproic Acid Delayed Release (Stavzor)

The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium ( Depakote , and others; Depakote ER ) is…

Med Lett Drugs Ther. 2009 Apr 6; 51(1309):27-8
The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium ( Depakote , and others; Depakote ER ) is approved: monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures; acute treatment of manic episodes associated with bipolar disorder; and prophylaxis of migraine headaches. In addition, valproate (valproic acid or divalproex sodium) is considered a drug of choice for treatment of other types of seizures including generalized tonic-clonic, myotonic and atonic seizures.